Comparability of biosimilar filgrastim with originator filgrastim: Protein characterization, pharmacodynamics, and pharmacokinetics

BioDrugs

Volumn 29, Issue 2, 2015, Pages 123-131

  Sörgel, Fritz ^a,b   Schwebig, Arnd ^c   Holzmann, Johann ^d   Prasch, Stefan ^d   Singh, Pritibha ^c   Kinzig, Martina ^a  

^a Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Sandoz Biopharmaceuticals   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CELL COUNT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HUMAN; MIDDLE AGED; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; BIOSIMILAR PHARMACEUTICALS; CELL COUNT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEUTROPHILS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84937765320     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0124-7     Document Type: Article

References (10)

1. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347-57.
2. Gascon P, Fuhr U, Sörgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419-29.
3. Blackstone EA, Fuhr JP Jr. Innovation and competition: will biosimilars succeed? The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc. 2012;9:24-7.
4. ® in Europe: what have we learned? Support Care Cancer. 2013;21:2925-32.
5. Verpoort K, Möhler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol. 2012;4:289-93.
6. McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther. 2013;93:315-7.
7. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22:1383-91.
8. Brockmeyer C, Saldi A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Pract. 2009;15:34-40.
9. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27:495-507.
10. Holzmann J, Hausberger A, Rupprechter A, Toll H. Top-down MS for rapid methionine oxidation site assignment in filgrastim. Anal Bioanal Chem. 2013;405:6667-74.